Marka Goldsmith News Today

Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in...

Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that...

01.02.2024 - REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) - Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the ...

(The Center Square) – Four years post-pandemic, a Detroit resident was sentenced for stealing unemployment benefits and ordered to pay $583,409 in restitution.

REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A.

Analysts at Wedbush started coverage on shares of Revolution Medicines (NASDAQ:RVMD – Get Free Report) in a research note issued to investors on Thursday, Briefing.com reports. The firm set an “outperform” rating and a $41.00 price target on the stock. Wedbush’s price target suggests a potential upside of 46.48% from the company’s current price. Several […]

Revolution Medicines (NASDAQ:RVMD – Free Report) had its target price lowered by JPMorgan Chase & Co. from $47.00 to $39.00 in a research note published on Tuesday morning, Benzinga reports. The brokerage currently has an overweight rating on the stock. A number of other brokerages also recently issued reports on RVMD. Oppenheimer increased their price […]

Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) has earned a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price […]

09.11.2023 - Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs Sandra Horning, M.D., Joins Revolution Medicines Board of ... Seite 1

The justices will hear arguments on Tuesday on whether the government can disarm people subject to restraining orders for domestic abuse.